CBD

CBD, Research

The FDA Wants to Help Cannabis Businesses Advance Research

During a recent webinar, the FDA detailed how its Drug Master Files process could speed up research, while keeping proprietary information secret.

CBD

Here’s What Else We Know About the White House Meetings on CBD

Among the new names on the list of entities seeking to discuss the FDA’s forthcoming rules on CBD products: American Bankers Association and Columbia Care.

CBD

FDA Approves Epidiolex for New Condition That Causes Benign Tumors, Seizures

Epidiolex contains cannabidiol, or CBD, extracted from cannabis plants, and was first approved to treat severe forms of epilepsy.

CBD

Hemp Groups to Meet with White House on FDA CBD Policy

The Food and Drug Administration drafted its long-awaited CBD policy, and sent it to the White House Office of Management and Budget for approval, a final step before publication.

CBD

Federal DOT Discusses Hemp Legalization’s Impact on Commercial Drivers

The US Department of Transportation committee heard a presentation and asked questions about how the passage of the 2018 Farm Bill, and proliferation of CBD, is affecting the nation’s commercial drivers.

CBD

From Law Enforcement to Retail, a New Coalition Forms to Focus on CBD Regulation

Consumer Brands Association, which counts among its members Kellogg’s, Coca-Cola Company, and PepsiCo, Inc., brought together a diverse group to focus on federal CBD policies.

CBD

Charlotte Figi, Who Inspired the Movement for CBD as Medicine, Dies

Figi’s story raised awareness about the potential for CBD to reduce seizures, and led to CBD legislation and research around the world.

CBD

In a First, a Cannabis-Derived Pharma Product Is Descheduled in the US

The DEA has taken Epidiolex, a CBD-based formula for rare forms of epilepsy, completely off its list of controlled substances. Why? The 2018 Farm Bill.

CBD

FDA Reopens CBD Public Comment, “Extending It Indefinitely”

The Agency is specifically looking to collect “scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.”

CBD, Congress

What’s in the US Food and Drug Administration’s CBD Report to Congress?

The FDA is reopening public comment, collaborating with global regulators on how to handle cannabinoids, and backing research on CBD and “dermal penetration.”

CBD, Hemp

FDA to Ag Regulators: “Fool’s Game” to Tell Americans They Can’t Use CBD Products

At NASDA Winter Policy Conference, USDA says it’s loosening DEA lab testing requirement for hemp, and FDA signals openness to non-pharma CBD products.

Business, CBD

Q&A: The Food Giants Push For “Smart Regulation” of CBD

Consumer Brands Association—think Kellogg's, Pepsi, etc.—has created a high-voltage advisory board to frame its advocacy approach.

CBD

FDA Says It “Cannot Conclude” That CBD Is Safe as a Food Additive

The CBD industry has long awaited the FDA’s regulatory approach to CBD products, which the agency says it will unveil “in the coming weeks.”

CBD, Congress

Mitch McConnell Pressures the FDA to Go Easy on Hemp-Derived CBD

The push could give CBD-based food additives and dietary supplements the green light.

CBD, Hemp

Here’s What People Want the FDA to Know About CBD

The FDA has been collecting public comments since April to inform CBD product rules, and the window closes tomorrow. From state ag regulators to New York’s Bar Association, here are some highlights.

CBD

FDA Extends Public Comment on Products Containing Cannabis

The agency, which will determine the future of the CBD industry, also provided an update on its information gathering. And yesterday, Canada’s health officials initiated a somewhat similar process.